Chai Discovery co-founders argue drug design is a scaling problem

In a Sequoia Capital interview, Josh Meier and Matt McPartlon say biology is a messy science best treated as an engineering problem: scaling data, models, and compute lets the model outlearn hand-built pipelines for drug design.

Featured · Josh Meier, Matt McPartlon